Catalyst Brief

← Calendar

Readoutin 45d

IDEAYA Biosciences — IDE196

Phase 3 primary completion: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma.

Date
Jan 2027
Type
Readout
Indication
Metastatic Uveal Melanoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.